NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Robert McKenzie as Non-Executive Chairman, effective Friday, June 27, following the completion of its acquisition of Isopogen WA, holder of StemSmart, a patented stem cell technology, according to a same-day filing with the Australian bourse.

McKenzie succeeds outgoing Non-Executive Chairman Christopher Ntoumenopoulos and will receive 5 million unquoted options.

exercisable at AU$0.07 each and expiring three years from the date of issue, the filing said.

The company also appointed Marian Sturm as Chief Scientific Officer.

Shares of the company rose 4% in recent trade.